Shengbin Shi

618 total citations
24 papers, 518 citations indexed

About

Shengbin Shi is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shengbin Shi has authored 24 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Immunology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shengbin Shi's work include Immunotherapy and Immune Responses (8 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Shengbin Shi is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Shengbin Shi collaborates with scholars based in China and United States. Shengbin Shi's co-authors include Chuangnian Zhang, Weiwei Wang, Pingsheng Huang, Huijuan Song, Zuoxing Niu, Deling Kong, Chen Li, Gaona Shi, Ju Zhang and Xiuyuan Zhang and has published in prestigious journals such as Biomaterials, Journal of Controlled Release and Journal of Hepatology.

In The Last Decade

Shengbin Shi

22 papers receiving 515 citations

Peers

Shengbin Shi

IMMUN

ONCOL

Karthik Tiruthani United States

Lihong Wang-Bishop United States

Jonathan Wilhelm United States

Shurong Zhou United States

Shuzhen Tan China

Ece Tavukçuoğlu Türkiye

Sarah Nietzer Germany

Feifei Yang China

Xuemeng Guo China

Karthik Tiruthani United States

Shengbin Shi

295 ×1.1

314 ×1.6

IMMUN

228 ×1.6

279 ×2.3

ONCOL

53 ×0.5

Citations per year, relative to Shengbin Shi Shengbin Shi (= 1×) peers Karthik Tiruthani

Countries citing papers authored by Shengbin Shi

Since Specialization

Citations

This map shows the geographic impact of Shengbin Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengbin Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengbin Shi more than expected).

Fields of papers citing papers by Shengbin Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengbin Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengbin Shi. The network helps show where Shengbin Shi may publish in the future.

Co-authorship network of co-authors of Shengbin Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Shengbin Shi. A scholar is included among the top collaborators of Shengbin Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengbin Shi. Shengbin Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Zhiting, Changrong Wang, Jing Wu, et al.. (2025). pH-responsive sparfloxacin/Fe3+ nanoparticles eradicate intratumoral bacteria and activate ferroptosis for enhanced antitumor immunotherapy in breast cancer. Biomaterials. 328. 123804–123804.

Li, Jia, et al.. (2025). Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2. Journal of Experimental & Clinical Cancer Research. 44(1). 232–232.

Xu, Minxuan, Junjie Zhao, Liancai Zhu, et al.. (2024). Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. Journal of Hepatology. 82(2). 277–300. 4 indexed citations

Song, Huijuan, Qi Su, Chuangnian Zhang, et al.. (2023). Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. Acta Biomaterialia. 158. 535–546. 27 indexed citations

Liu, Xiang, Jing-Rong Wang, Weijun Tian, et al.. (2023). Supramolecular Polymer‐Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage‐Reprogramming polyTLR7/8a Nanoregulator for Enhanced Anti‐Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma. Advanced Science. 10(22). e2300637–e2300637. 25 indexed citations

Zhang, Chuangnian, et al.. (2023). Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma. Cancer Immunology Immunotherapy. 72(11). 3727–3738. 12 indexed citations

Zhang, W., et al.. (2022). The full management from first-line to third-line treatments in patients with Her-2–negative advanced gastric cancer. Frontiers in Oncology. 12. 949941–949941. 4 indexed citations

Shi, Shengbin, et al.. (2021). Serum-derived exosomes function as tumor antigens in patients with advanced hepatocellular carcinoma. Molecular Immunology. 134. 210–217. 14 indexed citations

Miao, Feng, et al.. (2019). [Transmission electron microscopic observation on gonad of Oncomelania hupensis offspring bred in Weishan Lake areas].. PubMed. 32(2). 195–197. 1 indexed citations

10.

Shi, Shengbin, Quan Rao, Chuangnian Zhang, et al.. (2018). Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. Translational Oncology. 11(2). 250–258. 66 indexed citations

11.

Zhang, Chuangnian, Gaona Shi, Ju Zhang, et al.. (2017). Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. Journal of Controlled Release. 256. 170–181. 139 indexed citations

12.

Tian, Jing, et al.. (2016). Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma. OncoTargets and Therapy. Volume 9. 3901–3906. 4 indexed citations

13.

Tian, Jing, Ming Shang, Shengbin Shi, Yong Han, & Jun Xu. (2015). Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology. 76(4). 829–834. 11 indexed citations

14.

Shi, Shengbin, et al.. (2015). MicroRNA 25 , microRNA 145 , and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Translational research. 170. 1–7. 28 indexed citations

15.

Shi, Shengbin, et al.. (2014). Efficacy of Erlotinib Plus Dendritic Cells and Cytokine-induced Killer Cells in Maintenance Therapy of Advanced Non–Small Cell Lung Cancer. Journal of Immunotherapy. 37(4). 250–255. 27 indexed citations

16.

Zhao, Haitao, Jing Chen, Shengbin Shi, Jing Tian, & Rongjie Tao. (2014). Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma. Medical Oncology. 32(1). 351–351. 19 indexed citations

17.

Shi, Shengbin, et al.. (2014). Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI. Medical Oncology. 31(8). 63–63. 9 indexed citations

18.

Shi, Shengbin, et al.. (2013). Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment. Medical Oncology. 30(2). 550–550. 1 indexed citations

19.

Shi, Shengbin, et al.. (2013). [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].. PubMed. 35(4). 301–4. 1 indexed citations

20.

Shi, Shengbin, et al.. (2012). Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology. 12(6). 475–479. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact